New York’s insurance regulator formally notified a group of opioid manufacturers and distributors that the NYDFS will launch a civil enforcement action against them for contributing towards a rise in health insurance premiums in the state, said two sources familiar with the matter.
Pharma companies may not like their products being the subject of ICER reports, but they can provide a jumping-off point for manufacturers to expand the conversation of the value of new medicines in the rare disease area.
The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.
EVERSANA, the leading independent provider of global services to the life science industry, introduced a new suite of global market access solutions from Health Strategies Insights to help biopharmaceutical manufacturers understand the latest global trends in access, payment, distribution and administration.
As lawmakers in Congress are exploring potential price-lowering options for prescription drugs, Department of Health and Human Services Secretary Alex Azar is floating a proposed rule to lower the prices and out-of-pocket expenses by encouraging manufacturers to pass discounts to patients instead of insurers.
The difficulty behind new ideas, project management, drug prices, and the slowness and uncertainty of new product development are just some external and internal roadblocks that pharmaceutical leaders and employees face.
The U.S. Justice Department sought court permission to participate in settlement negotiations aimed at resolving lawsuits by state and local governments against opioid manufacturers and distributors.
U.S. Food and Drug Administration chief Scott Gottlieb criticized pharmacy benefit managers, health insurers and drugmakers for “Kabuki drug-pricing constructs” that profit the industry at the expense of consumers.
Heart devices that use software or wireless communications may be vulnerable to hacker attacks that could cause life-threatening malfunctions, U.S. cardiologists say.
U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light — more than double the previous year — while the figure also rose in the EU.